Waiv is a healthcare startup focused on catalyzing precision medicine through AI-enabled diagnostics in digital pathology. Leveraging over seven years of medical AI research, Waiv develops transformative tests that enhance biomarker discovery and optimize diagnostic workflows, making precision oncology accessible to patients globally. Waiv's products include clinically validated AI tests like RlapsRisk BC, designed to provide morphological insights that improve clinical diagnostic processes. Collaborating with leading medical institutions, Waiv aims to address the complexities and costs associated with biomarker testing as part of the broader shift towards precision care.